Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: A randomized study

Urologia Internationalis

Volumn 72, Issue 3, 2004, Pages 189-195

  Prezioso, Domenico ^a,b   Lotti, Tullio ^a   Polito, Mario ^a   Montironi, Rodolfo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE   (Italy)

Author keywords

Gonadotrophin releasing hormone; Leuprolide acetate; Neoadjuvant hormone therapy; Prostate cancer

Indexed keywords

CYPROTERONE ACETATE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADJUVANT THERAPY; ARTICLE; BLEEDING; CANCER LOCALIZATION; CANCER STAGING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EVALUATION; FLUSHING; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPERATION DURATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SWEATING; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; CYPROTERONE ACETATE; DELAYED-ACTION PREPARATIONS; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 1842840882     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077113     Document Type: Article

References (13)

1. Hamdy FC, Thomas BG: New therapeutic concepts in prostate cancer. BJU Int 2001;88:43-48.
2. Iselin CE, Robertson JE, Paulson DF: Radical perineal prostatectomy: Oncological outcome during a 20-year period. J Urol 1999;161:163-168.
3. Scolieri MJ, Altman A, Resnick MI: Neoadjuvant hormonal ablative therapy before radical prostatectomy: A review. Is it indicated? J Urol 2000;164:1465-1472.
4. Labrie F, Gomez JL, Cusan L, Diamond P, Fradet Y, Têtu B, et al: Neoadjuvant antiandrogen therapy for localized prostate cancer. Prospective and randomized clinical trial. J Endocrinol Invest 1994;17:61.
5. Kennedy TJ, Sonneland AM, Martlett MM, Troup RH: Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer. J Urol 1992;147:891-893.
6. Bourdin S, Karam G, Clemain P, Bouchot O, Peuvrel P, Lacoste J, et al: Clinical experience with leuprorelin acetate before radiotherapy for prostatic cancer. J Int Med Res 1990;18:74-78.
7. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, et al: Neoadjuvant hormonal therapy: The Canadian experience. Urology 1997;49:56-64.
8. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995;154:424-428.
9. Hugosson J, Abrahamsson PA, Ahlgern G, Aus G, Lundberg S, Schelin S, et al: The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 1996;29:413-419.
10. Witjes WP, Schulman CC, Debruyne FM: Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997;49:65-69.
11. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
12. Armas OA, Melamed A, Aprikian A, Cordon-Cardo C, Fair W, Reuter WE: Effect of preoperative androgen deprivation therapy in prostatic carcinoma. Lab Invest 1993;68:55A.
13. Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF: The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 1993;71(suppl):1031-1038.